Diagnosis and treatment with steroids for patients with Duchenne muscular dystrophy: experience and recommendations for Mexico

被引:4
作者
Vazquez-Cardenas, Norma A. [1 ,2 ]
Ibarra-Hernandez, Francisco [1 ,3 ,4 ]
Lopez-Hernandez, Luz B. [1 ,7 ]
Escobar-Cedillo, Rosa E. [8 ]
Ruano-Calderon, Luis A. [6 ]
Gomez-Diaz, Benjamin [8 ]
Garcia-Calderon, Noemi [1 ]
Fernanda Carriedo-Davila, M. [7 ]
Rojas-Hurtado, Liliana G. [7 ]
Luna-Padron, Emilia [5 ]
Coral-Vazquez, Ramon M. [9 ]
机构
[1] Asociac Distrofia Muscular Occidente AC, Guadalajara, Jalisco, Mexico
[2] Univ Autonoma Guadalajara, Guadalajara, Jalisco, Mexico
[3] Hosp Gen Reg 46, Guadalajara, Jalisco, Mexico
[4] Inst Mexicano Seguro Social, Guadalajara, Jalisco, Mexico
[5] Ctr Rehabil Infantil Teleton, Guadalajara, Jalisco, Mexico
[6] Hosp Gen Durango, Mexico City, DF, Mexico
[7] Ctr Med Nacl 20 Noviembre, Div Invest Biomed, Inst Seguridad & Serv Sociales Trabajadores Estad, Mexico City, DF, Mexico
[8] Secretaria Salud Mexico, Inst Nacl Rehabil, Mexico City, DF, Mexico
[9] Inst Politecn Nacl, Escuela Super Med, Mexico City, DF, Mexico
关键词
Deflazacort; DMD gene; Duchenne's muscular dystrophy; Dystrophin; Prednisone; Steroids; IMMUNIZATION PRACTICES ACIP; CORTICOSTEROID TREATMENT; DEFLAZACORT TREATMENT; ADVISORY-COMMITTEE; DOUBLE-BLIND; FOLLOW-UP; DISEASE; CHILDREN; INTERVENTIONS; PREVENTION;
D O I
10.33588/rn.5710.2013380
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Duchenne muscular dystrophy is a severe, debilitating and progressive disease that affects 1 in 3,500 live male births in the world. The diagnosis should be confirmed by genetic testing to identify the mutation in the DMD gene or muscle biopsy and immunostaining to demonstrate the absence of dystrophin. Although up to now continues to be an incurable disease, this does not mean it has no treatment. Treatment should be multidisciplinary, looking for the functionality of the patient and avoiding or correcting complications, mainly cardio-respiratory and skeletal. Many proposals have been evaluated and implemented with the aim of improving the quality of life for these patients. The long-term steroids have shown significant benefits, such as prolonging ambulation, reduce the need for spinal surgery, improve cardiorespiratory function and increase survival and the quality of life. This document presents the recommendations based on the experience of the working group and experts worldwide on the diagnosis and treatment with steroids for patients with Duchenne muscular dystrophy.
引用
收藏
页码:455 / 462
页数:8
相关论文
共 45 条
[1]   Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule [J].
Aartsma-Rus, Annemieke ;
Van Deutekom, Judith C. T. ;
Fokkema, Ivo F. ;
Van Ommen, Gert-Jan B. ;
Den Dunnen, Johan T. .
MUSCLE & NERVE, 2006, 34 (02) :135-144
[2]   Theoretic Applicability of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy Mutations [J].
Aartsma-Rus, Annemieke ;
Fokkema, Ivo ;
Verschuuren, Jan ;
Ginjaar, Leke ;
van Deutekom, Judith ;
van Ommen, Gert-Jan ;
den Dunnen, Johan T. .
HUMAN MUTATION, 2009, 30 (03) :293-299
[3]  
Abbs Stephen, 2010, Neuromuscul Disord, V20, P422, DOI 10.1016/j.nmd.2010.04.005
[4]   Rapid and cost effective detection of small mutations in the DMD gene by high resolution melting curve analysis [J].
Almomani, Rowida ;
van der Stoep, Nienke ;
Bakker, Egbert ;
den Dunnen, Johan T. ;
Breuning, Martijn H. ;
Ginjaar, Ieke B. .
NEUROMUSCULAR DISORDERS, 2009, 19 (06) :383-390
[5]  
Alvarez Leal M, 1994, Gac Med Mex, V130, P459
[6]   The role of corticosteroids in muscular dystrophy: A critical appraisal [J].
Angelini, Corrado .
MUSCLE & NERVE, 2007, 36 (04) :424-435
[7]   Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade [J].
Biggar, WD ;
Harris, VA ;
Eliasoph, L ;
Alman, B .
NEUROMUSCULAR DISORDERS, 2006, 16 (04) :249-255
[8]   Duchenne muscular dystrophy [J].
Biggar, WD .
PEDIATRICS IN REVIEW, 2006, 27 (03) :83-88
[9]   Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols [J].
Biggar, WD ;
Politano, L ;
Harris, VA ;
Passamano, L ;
Vajsar, J ;
Alman, B ;
Palladino, A ;
Comi, LI ;
Nigro, G .
NEUROMUSCULAR DISORDERS, 2004, 14 (8-9) :476-482
[10]   Deflazacort treatment of Duchenne muscular dystrophy [J].
Biggar, WD ;
Gingras, M ;
Fehlings, DL ;
Harris, VA ;
Steele, CA .
JOURNAL OF PEDIATRICS, 2001, 138 (01) :45-50